Oncolytic Virus CDMO Services Market Size, Share & Industry Analysis, By Service Type (Development & Technology-Transfer Services, Cell & Virus Banking Services, Manufacturing Services, and Analytical Testing & CMC Support Services), By Virus (Adenoviridae, Herpesviridae, Poxviridae, and Reoviridae), By Development Stage (Preclinical & IND-enabling, Phase I, Phase II, Phase III & Registration, and Commercial & Post-approval), By Sponsor Type (Small & Mid-sized Biotechnology Companies, Large Pharmaceutical Companies, and Academic & Research Institutions), and Regional Forecast, 2026-2034

The global oncolytic virus CDMO services market size was valued at USD 634.6 million in 2025. The market is projected to grow from USD 715.4 million in 2026 to USD 2,169.5 million by 2034, exhibiting a CAGR of 14.9% during the forecast period. North America dominated the oncolytic virus CDMO services market with a market share of 36.07% in 2025.

Oncolytic virus CDMO services enable biotechnology and pharmaceutical companies to accelerate the development of genetically engineered viruses designed to selectively infect and destroy cancer cells while stimulating anti-tumor immune responses. The market comprises contract development and manufacturing organizations that provide process development, analytical testing, GMP manufacturing, fill-finish, quality control, regulatory support, and commercial manufacturing services for oncolytic virus therapeutics. Market growth is attributed to increasing investment in cancer immunotherapy, growing clinical evaluation of virus-based therapeutics, and rising collaborations between biotechnology firms and specialized CDMOs. In addition, the complexity of viral vector production, stringent regulatory requirements, and the need for scalable GMP manufacturing are also expected to have a positive impact on market growth.

Key players in the market include FUJIFILM Biotechnologies, Lonza Group AG, Recipharm AB, IDT Biologika GmbH, and WuXi Advanced Therapies, are focusing on developing various innovative technologies to offer better products with improved accuracy and efficiency.

Download Free sample to learn more about this report.

Oncolytic Virus CDMO Services Market KEY TAKEAWAYS

Global Market Size & Forecast

• 2025 Market Size: USD 634.6 million
• 2026 Market Size: USD 715.4 million
• 2034 Forecast Market Size: USD 2,169.5 million
• CAGR: 14.9% from 2026–2034

Market Share

• North America dominated the oncolytic virus CDMO services market with a 36.07% share in 2025.
• Analytical testing & CMC support services is projected to grow at a 14.3% CAGR.
• Herpesviridae is projected to grow at a 15.7% CAGR.

Key Regional Highlights

North America

North America led the market with USD 228.9 million in 2025, supported by strong biotechnology activity and viral manufacturing infrastructure.

Europe

Europe is projected to grow at a 13.8% CAGR and reach USD 231.5 million in 2026.

Asia Pacific

Asia Pacific is estimated to reach USD 207.0 million in 2026, driven by expanding GMP viral manufacturing facilities.

U.S.

U.S. The market is estimated at approximately USD 231.2 million in 2026, representing about 32.3% of global sales.

Japan

Japan The market is estimated at approximately USD 38.6 million in 2026, accounting for about 5.4% of global revenues.

Read More

ONCOLYTIC VIRUS CDMO SERVICES MARKET TRENDS 

Integration of AI-Driven Process Development and Flexible GMP Manufacturing is a Prominent Trend Observed in Market

The integration of artificial intelligence, digital bioprocessing, and flexible GMP manufacturing platforms is emerging as a prominent trend in the market. CDMOs are increasingly adopting AI-enabled process optimization, automated quality monitoring, digital twins, and single-use bioprocessing technologies to improve manufacturing efficiency, reduce production timelines, and enhance product consistency. Simultaneously, investments in modular manufacturing facilities and scalable viral production platforms are enabling faster support for early-stage and commercial programs.

• For instance, in April 2024, Takara Bio launched large-scale viral vector contract manufacturing using Thermo Fisher's DynaDrive single-use bioreactors, enhancing scalable GMP production for gene and cell therapy developers.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Increasing Clinical Development of Oncolytic Virus Therapies to Drive Market Growth

The growing number of clinical-stage oncolytic virus therapies is a major factor responsible for the global oncolytic virus CDMO services market growth. Biotechnology companies are advancing engineered adenoviruses, herpes simplex viruses, vaccinia viruses, and other viral platforms for treating solid tumors and hematological malignancies. These products require specialized process development, GMP manufacturing, analytical characterization, and regulatory documentation that many developers cannot perform internally. As oncology pipelines continue to expand, outsourcing to experienced CDMOs enables sponsors to reduce development timelines, improve manufacturing scalability, and comply with evolving regulatory standards.

• For instance, in September 2022, MD Anderson Cancer Center and Virogin Biotech entered a five-year strategic collaboration to accelerate the clinical development of investigational oncolytic viruses and immunotherapies for advanced cancers through multiple clinical trials and biomarker research.

MARKET RESTRAINTS

High Manufacturing Complexity and Production Costs to Restrain Market Growth

The manufacturing of oncolytic viruses involves complex upstream and downstream processing, stringent contamination controls, specialized viral analytics, and highly regulated GMP environments, resulting in substantial production costs. Moreover, viral vector manufacturing also requires dedicated facilities, highly skilled personnel, and rigorous quality assurance procedures to ensure product consistency and safety. These requirements increase operational expenses for both sponsors and CDMOs while limiting manufacturing flexibility.

MARKET OPPORTUNITIES

Expansion of Precision Oncology and Combination Immunotherapy Programs Creates Significant Opportunities

The growing adoption of precision oncology and combination immunotherapy is creating substantial opportunities for oncolytic virus CDMO service providers. Developers are increasingly evaluating oncolytic viruses alongside immune checkpoint inhibitors, CAR-T therapies, monoclonal antibodies, and targeted therapies to enhance therapeutic efficacy. These combination approaches require customized manufacturing processes, analytical testing, clinical supply management, and regulatory support, increasing outsourcing demand. In addition, expanding investments in genetically modified viral platforms, personalized cancer therapies, and global oncology clinical trials are encouraging CDMOs to expand manufacturing capacity and introduce advanced viral production technologies to support future commercial requirements.

MARKET CHALLENGES

Increasing Regulatory Requirements and Limited Global Manufacturing Capacity Challenge Market Expansion

The evolving regulatory landscape and limited availability of specialized viral manufacturing facilities present significant challenges for the market. Regulatory agencies require extensive process validation, viral safety testing, potency assays, comparability studies, and long-term quality monitoring before clinical and commercial approval. Simultaneously, relatively few CDMOs possess the infrastructure and technical expertise required for large-scale GMP production of oncolytic viruses. Capacity constraints can extend manufacturing timelines and delay clinical programs.

Segmentation Analysis

By Service Type

Increased Investments in Automated Bioprocessing Technologies Boosted Manufacturing Services Segment Growth

Based on the service type, the market is divided into development & technology-transfer services, cell & virus banking services, manufacturing services, and analytical testing & CMC support services.

In 2025, manufacturing services held the highest global oncolytic virus CDMO services market share. Requirement of specialized manufacturing capabilities, along with production complexities in oncolytic virus to boost segment growth. Oncolytic viruses require complex upstream cell culture processes, downstream purification, analytical characterization, aseptic fill-finish, and compliance with stringent Good Manufacturing Practice (GMP) standards. Moreover, most biotechnology companies lack dedicated viral vector manufacturing infrastructure and therefore rely on CDMOs to ensure scalable, high-quality production from preclinical through commercial stages. In addition, growing investments in automated bioprocessing technologies, single-use manufacturing systems, and larger GMP facilities are further strengthening demand for outsourced manufacturing services.

• For instance, in October 2022, ABL Inc. partnered with Imugene to provide process development and GMP manufacturing services for the CF33 oncolytic virus platform, supporting clinical advancement of multiple oncology candidates.

The analytical testing & CMC support services segment is anticipated to rise with a CAGR of 14.3% over the forecast period.  

To know how our report can help streamline your business, Speak to Analyst

By Virus

Adenoviridae Segment Led Market Due to Its Higher Adoption in Cancer Immunotherapy

Based on virus, the market is segmented into adenoviridae, herpesviridae, poxviridae, reoviridae, and others.

In 2025, the adenoviridae segment held the highest market share, attributed to its well-established role in cancer immunotherapy and favorable biological characteristics. Furthermore, several biotechnology companies continue to advance adenovirus-based oncology programs targeting solid tumors, reinforcing the need for scalable GMP manufacturing capabilities and specialized viral production expertise throughout product development.

The herpesviridae segment is anticipated to rise with a CAGR of 15.7% over the forecast period.  

By Development Stage

Substantial Number of Candidates in Early Clinical Development Boosted Phase I Segment Growth

Based on development stage, the market is segmented into preclinical & IND-enabling, phase I, phase II, phase III & registration, and commercial & post-approval.

In 2025, the phase I segment held the highest market share. Companies developing novel viral immunotherapies prioritize first-in-human studies to establish safety, tolerability, dose escalation, biodistribution, and preliminary antitumor activity before advancing to later-stage trials. Each Phase I program requires GMP-grade clinical material, analytical testing, quality assurance, regulatory documentation, and manufacturing process optimization, creating substantial demand for CDMO services. Additionally, the expanding number of biotechnology companies entering the oncolytic virus field continues to increase outsourcing activities for early-stage manufacturing and clinical supply support.

The commercial & post-approval segment is anticipated to rise with a CAGR of 20.5% over the forecast period.

By Sponsor Type

Considerable Cost Management by Small & Mid-Sized Biotechnology Companies Accelerated Segment Growth

Based on sponsor type, the market is segmented into small & mid-sized biotechnology companies, large pharmaceutical & biopharmaceutical companies, academic & research institutions, and others.

In 2025, the small & mid-sized biotechnology companies segment held the largest market share. These organizations typically outsource process development, GMP manufacturing, analytical testing, quality control, regulatory support, and clinical supply management to specialized CDMOs to reduce capital investment and accelerate development timelines. The increasing availability of venture capital funding, strategic licensing agreements, and pharmaceutical collaborations has enabled biotechnology firms to expand their oncology pipelines. Consequently, growing dependence on experienced CDMO partners continues to drive outsourcing demand across early and mid-stage oncolytic virus development.

The large pharmaceutical & biopharmaceutical companies segment is anticipated to rise with a CAGR of 16.4% over the forecast period.

Oncolytic Virus CDMO Services Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the largest share in 2024, valued at USD 204.5 million, and also maintained the leading share in 2025, with USD 228.9 million. The regional growth is attributed to strong concentration of biotechnology companies developing oncolytic virus therapies and expansion of viral vector manufacturing infrastructure.  

U.S. Oncolytic Virus CDMO Services Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 231.2 million in 2026, accounting for roughly 32.3% of global sales.

Europe

Europe is projected to record a CAGR of 13.8% in the coming years and reach a valuation of USD 231.5 million in 2026. The region is estimated to witness considerable market growth due to increasing cross-border oncology clinical trials and strong collaboration between academic institutes and biotechnology companies.

U.K. Oncolytic Virus CDMO Services Market

The U.K. market in 2026 is estimated at around USD 56.3 million, representing roughly 7.9% of global revenues.

Germany Oncolytic Virus CDMO Services Market

Germany’s market is projected to reach approximately USD 53.5 million in 2026, equivalent to around 7.5% of global sales.

Asia Pacific

Asia Pacific is estimated to reach USD 207.0 million in 2026. Asia Pacific is expected to register strong growth due to rapid expansion of GMP viral manufacturing facilities in China, Japan, South Korea, and India.

Japan Oncolytic Virus CDMO Services Market

The Japan market in 2026 is estimated at around USD 38.6 million, accounting for roughly 5.4% of global revenues.

China Oncolytic Virus CDMO Services Market

China’s market is projected to be one of the largest globally, with 2026 revenues estimated at around USD 125.9 million, representing roughly 17.6% of global sales.

India Oncolytic Virus CDMO Services Market

The India market in 2026 is estimated at around USD 9.8 million, accounting for roughly 1.4% of global revenues.

Latin America and Middle East & Africa

The Latin America and Middle East & Africa regions are expected to witness moderate growth in this market space during the forecast period. The Latin America market is set to reach a valuation of USD 12.0 million in 2026. In the Middle East & Africa, the GCC is set to reach a value of USD 4.5 million in 2026.

South Africa Oncolytic Virus CDMO Services Market

The South Africa market is projected to reach around USD 1.6 million in 2026, representing roughly 0.2% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Top Companies Emphasize Strategic Facility Expansions and End-to-End CDMO Capabilities to Strengthen Their Market Positions

The global oncolytic virus CDMO services market exhibits a semi-consolidated competitive landscape, with specialized viral vector manufacturers and integrated CDMOs accounting for a significant share of the market. Prominent players in the market include FUJIFILM Biotechnologies, Lonza Group AG, Recipharm AB, IDT Biologika GmbH, and WuXi Advanced Therapies. These companies are strengthening their market position through strategic facility expansions, investments in GMP viral manufacturing infrastructure, process development capabilities, advanced analytical services, and end-to-end CDMO solutions.

• For instance, in October 2024, Thermo Fisher Scientific launched Accelerator Drug Development, an integrated CDMO and CRO platform that combines process development, GMP manufacturing, analytical testing, regulatory support, and clinical supply services.

Other notable companies operating in the market include ABL, Inc., uBriGene Biosciences Inc., OBiO Technology Corp., Ltd., Exothera S.A., and NAOBIOS. These companies are expected to focus on expanding viral vector manufacturing capacity and strengthening process development and analytical testing capabilities.

LIST OF KEY ONCOLYTIC VIRUS CDMO SERVICE COMPANIES PROFILED

• FUJIFILM Biotechnologies (U.S.)
• Lonza Group AG (Switzerland)
• Recipharm AB (Sweden)
• IDT Biologika GmbH (Germany)
• WuXi Advanced Therapies (U.S.)
• ABL, Inc. (U.S.)
• uBriGene Biosciences Inc. (U.S.)
• OBiO Technology Corp., Ltd. (China)
• Exothera S.A. (Belgium)
• NAOBIOS (France)

KEY INDUSTRY DEVELOPMENTS

• March 2026: SK pharmteco invested USD 100 million to expand viral vector manufacturing capabilities across its U.S. and France facilities.
• September 2024: Recipharm AB expanded its viral vector manufacturing capabilities through its GenIbet business, strengthening CDMO support for advanced therapy developers.
• June 2024: FUJIFILM Diosynth Biotechnologies expanded its viral vector manufacturing capacity in Texas to support increasing demand for gene and viral therapies.
• May 2024: SK pharmteco expanded its viral vector manufacturing operations to enhance process development and commercial-scale production for advanced therapy developers.
• September 2023: Charles River Laboratories expanded its cell and gene therapy CDMO network by investing in additional viral vector development and GMP manufacturing capabilities.

REPORT COVERAGE

The global oncolytic virus CDMO services market analysis includes a comprehensive study of the market size & forecast by all the market segments included in the report. It includes details on the market dynamics and market trends expected to drive the market over the forecast period. It provides information on key aspects, including an overview of technological advancements, the regulatory environment, and product launches. Additionally, it details partnerships, mergers & acquisitions, as well as key industry developments and investments by key regions. The global market research report also provides a depth competitive landscape with information on the market share and profiles of key operating players.

Request for Customization   to gain extensive market insights.

Report Scope and Segmentation